This thesis explores the therapeutic potential of N,N-Dimethyltryptamine (DMT), a naturally occurring psychedelic compound known for its intense but short-lasting psychoactive effects. Recent preclinical and clinical studies suggest that DMT may have neuroprotective, anti-inflammatory, and psychological healing properties, particularly in conditions like treatment-resistant depression, anxiety, and PTSD. Unlike other psychedelics, DMT also exhibits rapid onset and short duration, making it a promising candidate for controlled clinical use with minimal time burden. The thesis also examines DMT’s interactions with sigma-1 receptors, which play a key role in cellular stress response and neuroregeneration. Ethical, regulatory, and pharmacological considerations are discussed to evaluate its future integration into modern psychiatric and neurological therapy. Overall, DMT emerges as a high-potential molecule that warrants further clinical investigation for its role in next-generation therapeutics.